{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:54:34Z","timestamp":1792637674550,"version":"4.5.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"LimmaTech Biologics"},{"name":"University College London for the serology"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Safe and effective vaccines are urgently needed to prevent Klebsiella pneumoniae infections. We assessed safety and immunogenicity of a tetravalent bioconjugate vaccine Kleb4V, containing O antigen-polysaccharides of K. pneumoniae serotypes (O1v1, O2a, O2afg and O3b).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this observer-blind, randomized, placebo-controlled, phase I\/II trial (ClinicalTrials.gov NCT04959344), 166 healthy adults (16 aged 18\u201340 and 150 aged 55\u201370 years) were enrolled and randomized to receive 2 intramuscular injections of Kleb4V (16 or 64\u2005\u03bcg of total O antigen with or without adjuvant AS03) or placebo on days 1 and 57. While the primary outcome was safety, the secondary outcomes included vaccine antigen immunogenicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Kleb4V was well tolerated, with most solicited and unsolicited AEs of mild to moderate intensity. Kleb4V was immunogenic for all four vaccine-serotypes at both doses. O1v1, O2a and O2afg specific IgG increased after the 1st vaccination and IgG persisted at six months after the second vaccination. For three of the four vaccine-serotypes, the AS03-adjuvanted formulations showed a superior immune response. O3b responses were reduced compared to the other vaccine antigens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Kleb4V is the first K. pneumoniae conjugate vaccine candidate to reach clinical assessment. The Kleb4V bioconjugate was immunogenic and well tolerated in the target population of adults aged 55\u201370 years for the vaccine-serotypes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/infdis\/jiaf600","type":"journal-article","created":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T12:55:22Z","timestamp":1763816122000},"page":"e342-e351","source":"Crossref","is-referenced-by-count":16,"title":["Safety and Immunogenicity of a\n                    <i>Klebsiella pneumoniae<\/i>\n                    Tetravalent Bioconjugate Vaccine (Kleb4V) Administered to Healthy Adults: A First-in-Human Phase I\/II Randomized and Controlled Study"],"prefix":"10.1093","volume":"233","author":[{"given":"C","family":"Alaimo","sequence":"first","affiliation":[{"name":"LimmaTech Biologics AG , Schlieren ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Karaky","sequence":"additional","affiliation":[{"name":"Infection, Immunity and Inflammation, Great Ormond Street Institute of Child Health, University College London , London ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9435-8266","authenticated-orcid":false,"given":"R","family":"Lawrence","sequence":"additional","affiliation":[{"name":"Infection, Immunity and Inflammation, Great Ormond Street Institute of Child Health, University College London , London ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Bownes","sequence":"additional","affiliation":[{"name":"Infection, Immunity and Inflammation, Great Ormond Street Institute of Child Health, University College London , London ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Haffner","sequence":"additional","affiliation":[{"name":"Nuvisan , Neu-Ulm ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Kowarik","sequence":"additional","affiliation":[{"name":"LimmaTech Biologics AG , Schlieren ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0769-5242","authenticated-orcid":false,"given":"D","family":"Goldblatt","sequence":"additional","affiliation":[{"name":"Infection, Immunity and Inflammation, Great Ormond Street Institute of Child Health, University College London , London ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Martin","sequence":"additional","affiliation":[{"name":"LimmaTech Biologics AG , Schlieren ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"key":"2026031304520418800_jiaf600-B1","doi-asserted-by":"crossref","first-page":"ofad649","DOI":"10.1093\/ofid\/ofad649","article-title":"The global and regional prevalence of hospital-acquired carbapenem-resistant Klebsiella pneumoniae infection: a systematic review and meta-analysis","volume":"11","author":"Lin","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2026031304520418800_jiaf600-B2","doi-asserted-by":"crossref","first-page":"e0324151","DOI":"10.1371\/journal.pone.0324151","article-title":"The global burden of Klebsiella pneumoniae associated lower respiratory infection in 204 countries and territories, 1990\u20132021: findings from the global burden of disease study 2021","volume":"20","author":"Li","year":"2025","journal-title":"PLoS One"},{"key":"2026031304520418800_jiaf600-B3","first-page":"e131","article-title":"Child deaths caused by Klebsiella pneumoniae in sub-Saharan Africa and south Asia: a secondary analysis of Child Health and Mortality Prevention Surveillance (CHAMPS) data","volume":"5","author":"Verani","year":"2024","journal-title":"Lancet"},{"key":"2026031304520418800_jiaf600-B4","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1016\/j.vaccine.2024.02.072","article-title":"Vaccine value profile for Klebsiella pneumoniae","volume":"42","author":"Dangor","year":"2024","journal-title":"Vaccine"},{"key":"2026031304520418800_jiaf600-B5","doi-asserted-by":"crossref","first-page":"e0001612","DOI":"10.1371\/journal.pgph.0001612","article-title":"Causes of death identified in neonates enrolled through Child Health and Mortality Prevention Surveillance (CHAMPS), December 2016 \u2013December 2021","volume":"3","author":"MahtabI","year":"2023","journal-title":"PLOS Glob Public Health"},{"key":"2026031304520418800_jiaf600-B6","author":"World Health Organization"},{"key":"2026031304520418800_jiaf600-B7","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1007\/s40121-021-00533-4","article-title":"Current stage in the development of Klebsiella pneumoniae vaccines","volume":"10","author":"Assoni","year":"2021","journal-title":"Infect Dis Ther"},{"key":"2026031304520418800_jiaf600-B8","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0264-410X(86)90092-7","article-title":"Safety and immunogenicity of a polyvalent Klebsiella capsular polysaccharide vaccine in humans","volume":"4","author":"Cryz","year":"1986","journal-title":"Vaccine"},{"key":"2026031304520418800_jiaf600-B9","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/clinids\/23.1.179","article-title":"Immunogenicity of a 24-valent Klebsiella capsular polysaccharide vaccine and an eight-valent Pseudomonas O-polysaccharide conjugate vaccine administered to victims of acute trauma","volume":"23","author":"Campbell","year":"1996","journal-title":"Clin Infect Dis"},{"key":"2026031304520418800_jiaf600-B10","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1365-3083.1993.tb02594.x","article-title":"Bacterial lysates and ribosomes as inducers of specific immune responses: a comparative study","volume":"38","author":"B\u00e9n\u00e9","year":"1993","journal-title":"Scand J Immunol"},{"key":"2026031304520418800_jiaf600-B11","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/infdis\/jiae097","article-title":"Heptavalent O-antigen bioconjugate vaccine exhibiting differential functional antibody responses against diverse Klebsiella pneumoniae isolates","volume":"230","author":"Wantuch","year":"2024","journal-title":"J Infect Dis"},{"key":"2026031304520418800_jiaf600-B12","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/oxfordjournals.aje.a121620","article-title":"Efficacy of a \u201cmixed bacterial vaccine\u201d in prophylaxis of acute respiratory infections: possible role of interferon","volume":"99","author":"Rytel","year":"1974","journal-title":"Am J Epidemiol"},{"key":"2026031304520418800_jiaf600-B13","first-page":"e02994-19","article-title":"Vaccine protection against multidrug-resistant Klebsiella pneumoniae in a nonhuman primate model of severe lower respiratory tract infection","volume":"10","author":"Malachowaa","year":"2019","journal-title":"Am Soc Microbiol"},{"key":"2026031304520418800_jiaf600-B14","doi-asserted-by":"crossref","first-page":"160","DOI":"10.4103\/ijabmr.IJABMR_63_20","article-title":"Intradermal immunization with heat-killed Klebsiella pneumoniae leading to the production of protective immunoglobulin G in BALB\/c mice","volume":"11","author":"Kawser","year":"2021","journal-title":"Int J Appl Basic Med Res"},{"key":"2026031304520418800_jiaf600-B15","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.it.2023.08.005","article-title":"Klebsiella pneumoniae: adaptive immune landscapes and vaccine horizons","volume":"44","author":"Wantuch","year":"2023","journal-title":"Trends Immunol"},{"key":"2026031304520418800_jiaf600-B16","doi-asserted-by":"crossref","first-page":"6572","DOI":"10.3390\/ijms21186572","article-title":"The impact of insertion sequences on O-serotype phenotype and its O-locus-based prediction in Klebsiella pneumoniae O2 and O1","volume":"21","author":"Artyszuk","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2026031304520418800_jiaf600-B17","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.mib.2020.01.006","article-title":"The intersection of capsule gene expression, hypermucoviscosity and hypervirulence in Klebsiella pneumoniae","volume":"54","author":"Walker","year":"2020","journal-title":"Curr Opin Microbiol"},{"key":"2026031304520418800_jiaf600-B18","doi-asserted-by":"publisher","author":"Stanton","DOI":"10.1101\/2025.06.28.25330253"},{"key":"2026031304520418800_jiaf600-B19","doi-asserted-by":"crossref","first-page":"e201","DOI":"10.1016\/S2214-109X(23)00539-9","article-title":"The burden of bacterial antimicrobial resistance in the WHO African region in 2019: a cross-country systematic analysis","volume":"12","author":"Antimicrobial Resistance Collaborators","year":"2024","journal-title":"Lancet Glob Health"},{"key":"2026031304520418800_jiaf600-B20","doi-asserted-by":"crossref","first-page":"e0068022","DOI":"10.1128\/msphere.00680-22","article-title":"The development of immunological assays to evaluate the level and function of antibodies induced by Klebsiella pneumoniae O-antigen vaccines","volume":"8","author":"Wagstaffe","year":"2023","journal-title":"mSphere"},{"key":"2026031304520418800_jiaf600-B21","doi-asserted-by":"crossref","first-page":"ofad417","DOI":"10.1093\/ofid\/ofad417","article-title":"Safety, reactogenicity, immunogenicity, and dose selection of 10-valent extraintestinal pathogenic Escherichia coli bioconjugate vaccine (VAC52416) in adults aged 60\u201385 years in a randomized, multicenter, interventional, first-in-human, phase 1\/2a study","volume":"10","author":"Fierro","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2026031304520418800_jiaf600-B22","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/icb.1982.65","article-title":"Resistance to Klebsiella pneumoniae and the importance of two bacterial antigens","volume":"60","author":"Cooper","year":"1982","journal-title":"Immunol Cell Biol"},{"key":"2026031304520418800_jiaf600-B23","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1001\/jama.1969.03160080043009","article-title":"Hyposensitization with bacterial vaccine in infectious asthma. A double-blind study and a longitudinal study","volume":"208","author":"Mueller","year":"1969","journal-title":"JAMA"},{"key":"2026031304520418800_jiaf600-B24","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/S0264-410X(94)80054-4","article-title":"Phase 1 trial of a 24-valent Klebsiella capsular polysaccharide vaccine and an eight-valent Pseudomonas O-polysaccharide conjugate vaccine administered simultaneously","volume":"12","author":"Edelman","year":"1994","journal-title":"Vaccine"},{"key":"2026031304520418800_jiaf600-B25","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/infdis\/174.3.537","article-title":"Immunoprophylaxis against Klebsiella and Pseudomonas aeruginosa infections. The Federal Hyperimmune Immunoglobulin Trial Study Group","volume":"174","author":"Donta","year":"1996","journal-title":"J Infect Dis"},{"key":"2026031304520418800_jiaf600-B26","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1080\/14760584.2021.1984889","article-title":"Recent advances in lipopolysaccharide-based glycoconjugate vaccines","volume":"20","author":"Zhu","year":"2021","journal-title":"Exp Rev Vaccines"},{"key":"2026031304520418800_jiaf600-B27","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.3389\/fmicb.2020.01249","article-title":"The diversity of lipopolysaccharide (O) and capsular polysaccharide (K) antigens of invasive Klebsiella pneumoniae in a multi-country collection","volume":"11","author":"Choi","year":"2020","journal-title":"Front Microbiol"},{"key":"2026031304520418800_jiaf600-B28","doi-asserted-by":"crossref","first-page":"e0203143","DOI":"10.1371\/journal.pone.0203143","article-title":"Development of a broad spectrum glycoconjugate vaccine to prevent wound and disseminated infections with Klebsiella pneumoniae and Pseudomonas aeruginosa","volume":"13","author":"Hegerle","year":"2018","journal-title":"PLoS One"},{"key":"2026031304520418800_jiaf600-B29","doi-asserted-by":"crossref","first-page":"100988","DOI":"10.1016\/j.lanmic.2024.100988","article-title":"Antibody responses in Klebsiella pneumoniae bloodstream infection: a prospective cohort study","volume":"6","author":"Hwang","year":"2025","journal-title":"Lancet Microbe"},{"key":"2026031304520418800_jiaf600-B30","doi-asserted-by":"crossref","first-page":"20701","DOI":"10.1038\/s41598-024-71487-z","article-title":"Klebsiella LPS O1-antigen prevents complement-mediated killing by inhibiting C9 polymerization","volume":"14","author":"Masson","year":"2024","journal-title":"Sci Rep"},{"key":"2026031304520418800_jiaf600-B31","author":"Lentini"},{"key":"2026031304520418800_jiaf600-B32","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jhin.2025.04.036","article-title":"Postoperative risk of infection with Klebsiella in adults\u2014a retrospective case\u2014control study","volume":"162","author":"Mulier","year":"2025","journal-title":"J Hosp Infect"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaf600\/65500279\/jiaf600.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/233\/2\/e342\/65500279\/jiaf600.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/233\/2\/e342\/65500279\/jiaf600.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T08:53:04Z","timestamp":1773391984000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/233\/2\/e342\/8342415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":32,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,11,25]]},"published-print":{"date-parts":[[2026,2,18]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaf600","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2,15]]},"published":{"date-parts":[[2025,11,25]]}}}